Sahajanand Medical Technologies Plans Initial Public Offering
Sahajanand Medical Technologies, founded in 2001 by Dhirajlal Kotadia, is gearing up for an initial public offering (IPO) to raise funds. The company has a significant presence across 76 countries, offering medical devices for various healthcare needs.
Key Details of the IPO
The upcoming IPO will see the offering of up to 2.76 crore equity shares on the National Stock Exchange of India Ltd. and BSE Ltd. The offer for sale will involve promoters Shree Hari Trust and Dhirajkumar Savjibhai Vasoya, along with investors like Samara Capital Markets Holding Ltd. and Kotak Pre-IPO Opportunities Fund.
The IPO’s book-running lead managers include Motilal Oswal Investment Advisors Ltd., Avendus Capital Pvt., and HSBC Securities, reflecting the company’s strong financial backing and support.
Focus on Innovation and Development
Sahajanand Medical Technologies specializes in Class III and Class C/D medical devices, focusing on Vascular Intervention and Structural Heart areas. Their product portfolio includes coronary stents, balloons, transcatheter aortic valves, and occluders, among others.
One of their notable innovations is the LDZ link, enhancing the delivery of their flagship biodegradable polymer DES, Supraflex Cruz. They have also developed the Aortic Valve Delivery Catheter (AVDC) system for their Hydra TAVI, showcasing their commitment to cutting-edge technology in healthcare.
Financial Performance and Growth
In the fiscal year 2025, Sahajanand Medical Technologies reported a revenue of Rs 1,024.88 crore, marking a 13.67% increase from the previous year. The company also turned a profit of Rs 25.15 crore, demonstrating solid financial performance and growth.
This move towards an IPO signifies the company’s ambition to expand its reach and further strengthen its position in the medical devices market.
For more information on Sahajanand Medical Technologies IPO and its impact on the healthcare industry, visit NDTV Profit.
